Stock profile

Baijin Life Science Holdings Limited(1466.HK)

Country: Hong KongSector: HealthcareIndustry: Drug Manufacturers - Specialty & GenericExchange: HKSE
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
881.65M
Currency HKD
KvantraRankiN/ANot enough data to calculate KvantraRank
Value41
Quality47
MomentumN/A
Current price
1.09+5.83%
Benchmarks

No price history available.

Key financial summary

Financials in HKD
2020202120222023202420252026TTM2027E
Total revenueHKDm1124363875413689N/AN/A
Operating profitHKDmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net profitHKDm-282-52-159-7-0-38N/AN/A
EPS reportedHKDLockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating cashflow per shareHKDLockedLockedLockedLockedLockedLockedLockedLockedLocked
Capex per shareHKDLockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF per shareHKDLockedLockedLockedLockedLockedLockedLockedLockedLocked
Free cash flowHKDmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debtHKDmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Book value equityHKDmLockedLockedLockedLockedLockedLockedLockedLockedLocked
Book value per shareHKDLockedLockedLockedLockedLockedLockedLockedLockedLocked
Number of sharesmLockedLockedLockedLockedLockedLockedLockedLockedLocked
DPS (TTM paid)HKDLockedLockedLockedLockedLockedLockedLockedLockedLocked

Financial summary

Financials in HKD
2020202120222023202420252026TTM2027E
Value
P/E LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/B LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/S LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
P/FCF LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EV/EBITDA LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EV/Sales LTMxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Earnings Yield LTM%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF Yield%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Quality
ROE%LockedLockedLockedLockedLockedLockedLockedLockedLocked
ROIC%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating margin%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Gross margin%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF/Sales%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Growth and momentum
EPS Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Sales Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Net Income Growth YoY%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Operating Profit Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Dividend and capital structure
Dividend Yield%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Dividend Growth%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Payout Ratio%LockedLockedLockedLockedLockedLockedLockedLockedLocked
FCF/DebtxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net Debt/EBITDAxLockedLockedLockedLockedLockedLockedLockedLockedLocked
EBIT/Net interestxLockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/market cap%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Net debt/Equity%LockedLockedLockedLockedLockedLockedLockedLockedLocked
Gross debt/equity%LockedLockedLockedLockedLockedLockedLockedLockedLocked

Ratings

Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked
Number of covering analystsLocked

Based on consensus from external analysts. Not Kvantra's opinion.

Company overview

Affluent Partners Holdings Limited, an investment holding entity founded in 2014 and situated in Central, Hong Kong, conducts various operations. Its core business involves the full lifecycle of pearls and jewelry products, including their acquisition, processing, design, manufacturing, assembly, trading, and wholesale distribution. The company's activities are structured into two distinct divisions: the sale of pearl and jewelry items, and strategic investment alongside financial services. Additionally, it allocates capital to financial assets within the real estate sector. Affluent Partners operates internationally, with a footprint in Hong Kong, the United Kingdom, the United States, Japan, Europe, and mainland China. This enterprise was previously known as Man Sang Jewellery Holdings Limited, undergoing a name change to Affluent Partners Holdings Limited in February 2017.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryHong Kong
Trades inHKD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Baijin Life Science Holdings Limited (1466.HK)

1466.HK · HKSE · Healthcare
1.09+5.83%
Sign up to track this stock

No price history available.

KvantraRankN/A
P/E TTMN/A
P/E NTMN/A
Market cap881.65M
KvantraRank?

Not enough data to calculate KvantraRank

Financialsin HKD
20242025TTM2026
Ratings
Strong Buy
Locked
Buy
Locked
Hold
Locked
Sell
Locked
Strong Sell
Locked

Based on consensus from external analysts. Not Kvantra's opinion.

About

Affluent Partners Holdings Limited, an investment holding entity founded in 2014 and situated in Central, Hong Kong, conducts various operations. Its core business involves the full lifecycle of pearls and jewelry products, including their acquisition, processing, design, manufacturing, assembly, trading, and wholesale distribution. The company's activities are structured into two distinct divisions: the sale of pearl and jewelry items, and strategic investment alongside financial services. Additionally, it allocates capital to financial assets within the real estate sector. Affluent Partners operates internationally, with a footprint in Hong Kong, the United Kingdom, the United States, Japan, Europe, and mainland China. This enterprise was previously known as Man Sang Jewellery Holdings Limited, undergoing a name change to Affluent Partners Holdings Limited in February 2017.

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CountryHong Kong
Trades inHKD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data for this stock

Unlimited access to every company

See plans

Unlock all fundamental data for this stock

Unlimited access to every company

See plans